Get the Stockscreener App
12.95
3.14%
-0.42
After Hours:
13.69
0.74
+5.71%
Neuropace Inc stock is traded at $12.95, with a volume of 211.70K.
It is down -3.14% in the last 24 hours and up +24.28% over the past month.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
See More
Previous Close:
$13.37
Open:
$13.6
24h Volume:
211.70K
Relative Volume:
0.95
Market Cap:
$382.88M
Revenue:
$65.42M
Net Income/Loss:
$-32.96M
P/E Ratio:
-10.20
EPS:
-1.27
Net Cash Flow:
$-19.87M
1W Performance:
+10.78%
1M Performance:
+24.28%
6M Performance:
+41.53%
1Y Performance:
+52.00%
1-Day Range:
$12.91
$13.61
1-Week Range:
$11.56
$13.61
52-Week Range:
$5.45
$15.11
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
12.95 | 382.88M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
129.05 | 231.50B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.95 | 154.04B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
387.53 | 144.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.11 | 105.58B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.50 | 43.95B | 5.54B | 4.18B | 623.10M | 7.00 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
NeuroPace Reports Strong Q1 2025 Revenue Growth - TipRanks
NeuroPace, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:NPCE) - Seeking Alpha
Earnings call transcript: NeuroPace beats Q1 2025 EPS forecast, stock rises - Investing.com Nigeria
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq
NeuroPace Inc SEC 10-Q Report - TradingView
Neuropace Inc reports results for the quarter ended March 31Earnings Summary - TradingView
NeuroPace Q1 2025 presentation: revenue jumps 24%, expands epilepsy treatment market - Investing.com Australia
Neuropace, Inc. Q1 Revenue USD 22.524 Million Versus. IBES Estimate USD 21.8 Million - marketscreener.com
NeuroPace Inc.: Q1 Earnings Snapshot - News-Times
NeuroPace Reports First Quarter 2025 Financial Results - The Manila Times
NeuroPace (NPCE) to Release Earnings on Wednesday - Defense World
Recent Price Trend in NeuroPace (NPCE) is Your Friend, Here's Why - Yahoo Finance
NeuroPace, Inc. (NASDAQ:NPCE) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable - simplywall.st
NeuroPace, Inc. (NASDAQ:NPCE) Shares Acquired by Wells Fargo & Company MN - Defense World
NeuroPace (NPCE) to Release Quarterly Earnings on Wednesday - MarketBeat
Barclays PLC Acquires 6,976 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
JPMorgan Chase & Co. Purchases 52,829 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Nantahala Capital Management LLC Sells 45,817 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Study: NeuroPace’s Technology Can Help Reduce Epileptic Seizures - Medical Product Outsourcing
28,547 Shares in NeuroPace, Inc. (NASDAQ:NPCE) Purchased by Walleye Capital LLC - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Shares Acquired by JPMorgan Chase & Co. - Defense World
Retail investors who hold 34% of NeuroPace, Inc. (NASDAQ:NPCE) gained 10%, institutions profited as well - simplywall.st
Geode Capital Management LLC Has $3.62 Million Stock Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Short Interest in NeuroPace, Inc. (NASDAQ:NPCE) Rises By 45.8% - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Sees Significant Growth in Short Interest - Defense World
NeuroPace Inc (NPCE) Trading Down 3.19% on Apr 15 - GuruFocus
NeuroPace expects minimal tariff impact, maintains guidance By Investing.com - Investing.com South Africa
NeuroPace expects minimal impact of tariffs on its operations and financial results - MSN
Neuropace Provides Update On Tariff Status - marketscreener.com
NeuroPace Reports 'Minimal impact' From Trump Tariffs - marketscreener.com
NeuroPace Expects Minimal Impact from Trade Tariffs - TipRanks
NeuroPace expects minimal tariff impact, maintains guidance - Investing.com Australia
NeuroPace Provides Update on Tariff Status - The Manila Times
US Manufacturing Shield: NeuroPace Dodges Tariff Headwinds as Peers Struggle - Stock Titan
NeuroPace stock target cut to $17 by Cantor Fitzgerald - Investing.com Australia
Contrasting DIH Holding US (NASDAQ:DHAI) & NeuroPace (NASDAQ:NPCE) - Defense World
What is Leerink Partnrs' Forecast for NeuroPace Q1 Earnings? - MarketBeat
Cantor Fitzgerald cuts NeuroPace stock target to $17 By Investing.com - Investing.com Canada
Cantor Fitzgerald cuts NeuroPace stock target to $17 - Investing.com
NeuroPace reports 82% seizure reduction in epilepsy study By Investing.com - Investing.com Australia
NeuroPace Reports Data From 3-year Post-Approval Study Of RNS System In Focal Epilepsy - Nasdaq
NeuroPace reports 82% seizure reduction in epilepsy study - Investing.com
NeuroPace announces data from long-term post-approval study of RNS System - TipRanks
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):